<DOC>
	<DOCNO>NCT00778908</DOCNO>
	<brief_summary>Based radiobiological finding accelerate tumor repopulation nasopharyngeal carcinoma occur late-course radiation therapy , investigator hypothesize intensity-modulated radiation therapy ( IMRT ) concomitant boost schedule increase daily dose start fifth week initiation IMRT might improve tumor control decrease treatment toxicity locoregionally advance nasopharyngeal carcinoma . The study design test late-course accelerate hyperfractionated IMRT improve outcome compare conventionally fractionate IMRT newly diagnose patient locoregionally advanced nasopharyngeal carcinoma .</brief_summary>
	<brief_title>Late-Course Accelerated Hyperfractionated IMRT Locoregionally Advanced Nasopharyngeal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically proven nonkeratinizing undifferentiated type nasopharyngeal carcinoma primary treatment curative intent According AJCC 2002 Staging System , clinical stage must ⅡbⅣb Age 1870 Karnofsky performance status ≥70 WBC ≥4,000/mm3 , PLT ≥ 100,000/mm3 , serum creatinine ≤ 1.6 mg/dl Without radiotherapy chemotherapy Signed studyspecific consent form prior study entry Patients distant metastasis Pregnant lactate woman The presence uncontrolled lifethreatening illness Patients receive radiotherapy chemotherapy previously</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Nasopharyngeal carcinoma</keyword>
	<keyword>Locally advanced disease</keyword>
	<keyword>Intensity-modulated radiation therapy</keyword>
	<keyword>Accelerated hyperfractionation</keyword>
	<keyword>Concomitant boost radiation therapy</keyword>
	<keyword>Concurrent chemotherapy</keyword>
</DOC>